[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Australian RCT (n=200) found that lutetium-177, a radiolabelled small molecule, led to a higher PSA response (66% vs 44%; difference 23%; p=0.0016) and fewer grade 3 or 4 adverse events (33% vs 53%) suggesting its potential as an alternative to cabazitaxel.

The Lancet